Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors ...Middle East

SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- On September 9th, 2023, Biosyngen Pte Ltd (hereafter as "Biosyngen") announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial of BRL03 for the treatment of lung cancer, gastric cancer and...

Hence then, the article about biosyngen received fda approval for phase i ii clinical trials for brl03 targeting lung cancer gastric cancer and other advanced solid tumors was published today ( Monday 11/09/2023 - 09:49 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors )

Also on site :

• Teen gang member dies in custody
• Fortnite Ben 10 collaboration: Release date, what to expect & more
• Exclusive: Omni raises $120 million to fix one of AI’s biggest enterprise data problems